Group – Talk Bio

ViiV Healthcare’s Multifaceted Approach to Combating HIV in Black Communities

2 months ago talkbio0Tagged Black Populations, care activity, Community, community grants, HIV Prevention, Indication of (contextual qualifier), Risk, Social stigmata, ViiV Healthcare

ViiV Healthcare, HIV prevention, Black communities, Risk to Reasons, community grants, stigma reduction, education, access to care

NFL Legend Jerome Bettis Joins CDC Foundation’s “Live to the Beat” Campaign to Tackle Heart Health in Black Community

3 months ago talkbio0Tagged beat, Bettis, Black Populations, Cardiovascular Diseases, Centers for Disease Control and Prevention (U.S.), Community, Foundations, heart health, Hypertensive disease, Jerome, NEFL gene

Jerome Bettis, CDC Foundation, Live to the Beat, cardiovascular disease, Black community, hypertension, heart health, NFL

Empowering Undergraduates: Johns Hopkins BME Design Team Transforms Healthcare Solutions

6 months ago talkbio0Tagged biomedical engineering field, Clinical Challenges, Design, Entrepreneurship, healthcare innovation, Intellectual Property, Principles, projects, regulatory frameworks, Team, Team-Based, Undergraduate Design

Biomedical Engineering, Undergraduate Design Team, Healthcare Innovation, Clinical Challenges, Design Principles, Team-Based Projects, Entrepreneurship, Intellectual Property, Regulatory Frameworks

WuXi AppTec Continues to Attract New Clients Amid BIOSECURE Act Uncertainty

6 months ago talkbio0Tagged AppTec, BIOSECURE, chain vulnerabilities, Chinese, Chinese contract manufacturer, Clients, Drug Industry, Senate consideration, WuXi

WuXi AppTec, BIOSECURE Act, new clients, revenue decline, Chinese contract manufacturer, U.S. Senate consideration, pharmaceutical industry, supply chain vulnerabilities.

Mitigating Risks in mRNA Manufacturing: Strategies for Smooth Transition from Preclinical to Clinical Stages

6 months ago talkbio0Tagged analytical method, Automation, bony process, clinical transition, Control Groups, Materials, Preclinical, Quality, regulatory, Risk Management, RNA, Messenger

mRNA manufacturing, risk management, preclinical to clinical transition, quality control, regulatory compliance, raw material selection, process automation, analytical methods.